Neoadjuvant Chemotherapy and Nivolumab in Resectable Non–Small Cell Lung Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant Chemotherapy and Nivolumab in Resectable Non-Small-Cell Lung Cancer (NADIM): An Open-Label, Multicentre, Single-Arm, Phase 2 Trial
Lancet Oncol 2020 Sep 24;[EPub Ahead of Print], M Provencio, E Nadal, A Insa, MR García-Campelo, J Casal-Rubio, M Dómine, M Majem, D Rodríguez-Abreu, A Martínez-Martí, J De Castro Carpeño, M Cobo, G López Vivanco, E Del Barco, R Bernabé Caro, N Viñolas, I Barneto Aranda, S Viteri, E Pereira, A Royuela, M Casarrubios, C Salas Antón, ER Parra, I Wistuba, V Calvo, R Laza-Briviesca, A Romero, B Massuti, A Cruz-BermúdezFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.